"MART-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
| Descriptor ID |
D058965
|
| MeSH Number(s) |
D12.776.624.301.750 D23.050.285.439.750
|
| Concept/Terms |
MART-1 Antigen- MART-1 Antigen
- Antigen, MART-1
- MART 1 Antigen
- MART1 Antigens
- Antigens, MART1
- MelanA
- Melanoma Antigen Recognized by T-Cells 1
- Melanoma Antigen Recognized by T Cells 1
- MART1 Antigen
- Antigen, MART1
- Melan-A
- Melan A
|
Below are MeSH descriptors whose meaning is more general than "MART-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "MART-1 Antigen".
This graph shows the total number of publications written about "MART-1 Antigen" by people in this website by year, and whether "MART-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MART-1 Antigen" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Diagnostic utility of SOX10 immunostaining in benign lichenoid keratosis: A study of 21 cases. J Cutan Pathol. 2023 Jan; 50(1):51-55.
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
-
Atypical histopathologic features in a melanocytic nevus after cryotherapy and pregnancy. J Cutan Pathol. 2014 Oct; 41(10):802-5.
-
Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013 Sep; 26(9):1153-60.
-
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.
-
Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012 Feb; 255(2):357-62.
-
Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011 Aug; 18(8):827-34.
-
Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol. 2010 Jun 01; 184(11):6514-21.
-
Expression of Sox-9 in metastatic melanoma--a potential diagnostic pitfall. Am J Dermatopathol. 2010 May; 32(3):262-266.